|
gptkbp:instanceOf
|
gptkb:sedative
gptkb:benzodiazepine
|
|
gptkbp:approvedBy
|
1934
|
|
gptkbp:ATCCode
|
N05CA02
|
|
gptkbp:brand
|
gptkb:Seconal_Sodium
Sodium Seconal
|
|
gptkbp:CASNumber
|
76-73-9
|
|
gptkbp:chemicalFormula
|
C12H18N2O3
|
|
gptkbp:color
|
red
|
|
gptkbp:contraindication
|
gptkb:porphyria
severe respiratory disease
|
|
gptkbp:discoveredBy
|
gptkb:Donalee_L._Tabern
gptkb:Ernest_H._Volwiler
|
|
gptkbp:discoveredIn
|
1934
|
|
gptkbp:duration
|
short-acting
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
capsule
|
|
gptkbp:genericName
|
gptkb:secobarbital_sodium
|
|
gptkbp:legalStatus
|
Schedule II controlled substance (US)
|
|
gptkbp:marketedAs
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:relatedTo
|
gptkb:pentobarbital
phenobarbital
|
|
gptkbp:riskFactor
|
abuse
overdose
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
confusion
dizziness
drowsiness
respiratory depression
|
|
gptkbp:usedFor
|
treatment of insomnia
preoperative sedation
|
|
gptkbp:usedIn
|
physician-assisted suicide (in some jurisdictions)
|
|
gptkbp:withdrawn
|
some countries
|
|
gptkbp:bfsParent
|
gptkb:Secobarbital
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Seconal
|